AZN has been the topic of several other reports. Credit Suisse Group reiterated an outperform rating and issued a GBX 5,800 ($80.13) target price on shares of AstraZeneca in a report on Tuesday, February 20th. Goldman Sachs Group set a GBX 3,800 ($52.50) target price on shares of AstraZeneca and gave the company a sell rating in a report on Monday, February 19th. UBS Group reiterated a neutral rating on shares of AstraZeneca in a report on Monday, January 15th. Deutsche Bank reiterated a buy rating and issued a GBX 5,600 ($77.37) target price on shares of AstraZeneca in a report on Wednesday, November 1st. Finally, JPMorgan Chase & Co. reiterated a neutral rating on shares of AstraZeneca in a report on Friday, November 10th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of GBX 5,201.87 ($71.87).
AstraZeneca (LON:AZN) opened at GBX 4,775 ($65.97) on Monday. The firm has a market cap of $61,120.00 and a PE ratio of 2,776.16. AstraZeneca has a fifty-two week low of GBX 4,260 ($58.86) and a fifty-two week high of GBX 5,520 ($76.26).
In other AstraZeneca news, insider Philip A. J. Broadley bought 415 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The shares were purchased at an average cost of GBX 4,846 ($66.95) per share, with a total value of £20,110.90 ($27,785.16).
TRADEMARK VIOLATION WARNING: This article was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3229507/astrazeneca-azn-given-a-gbx-5075-price-target-by-jefferies-group-analysts.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.